Figure 6. PLK1 insufficiency is responsible for the mitotic defects in Nup88^T MEFs.

(A) Chromosome missegregation analysis of H2B-mRFP–positive MEFs expressing an shRNA against Plk1 or treated with 100 nM of the PLK1 inhibitor, BI2536. (B) Chromosome missegregation analysis of H2B-mRFP–positive MEFs overexpressing PLK1. Analyses in A and B were performed on at least 3 independent lines per genotype (25 cells/line). Data represent the mean ± SEM. Statistical significance was determined in A using a 1-way ANOVA, followed by Tukey’s multiple comparisons test to compare the control shRNA versus Plk1 shRNAs and a 2-tailed, unpaired t test to compare DMSO versus BI2536 treatment. Statistical significance was determined in B using a 1-way ANOVA, followed by Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, and ***P < 0.001. Nup88^T indicates the combined transgenic lines 11 and 13.